hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06272344 id: CHUBX 2022/38 briefTitle: Remote Programming of Cardiac Implantable Electronic Devices 2 acronym: REACT 2 overallStatus: RECRUITING date: 2023-04-24 date: 2024-10-24 date: 2024-10-24 date: 2024-02-22 date: 2024-02-22 name: University Hospital, Bordeaux class: OTHER briefSummary: Cardiac Implantable Electronic Devices (CIEDs) such as pacemakers and implantable cardioverter defibrillators need to be regularly and systematically interrogated and reprogrammed to ensure proper functioning. While remote monitoring allows for partial interrogation at a remote location, full CIED check-up and reprogramming is only possible when the patient visits a cardiologist capable of performing device programming. This can be challenging for patients and may cause unnecessary delays, particularly in settings of limited resources, enforced physical distancing, and quarantines. In this study we aim to evaluate our previously validated remote programming solution (REACT study, NCT05366660) in outpatient device clinics which are close to the patient's home but remote from the CIED expert. conditions: Pacemaker conditions: Defibrillator conditions: Telemedecine studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, single-center, single-arm, pairwise comparison trial primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 50 type: ESTIMATED name: Teleconsultation measure: assess the satisfaction of patients benefiting from a teleconsultation compared to a standard consultation at hospital measure: Time saving for patient measure: Savings on medical transport measure: Costs associated with teleconsultation measure: safety of teleconsultation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bordeaux University Hospital status: RECRUITING city: Pessac zip: 33604 country: France name: Sylvain MD Ploux role: CONTACT phone: (0)5 57 65 64 71 phoneExt: +33 email: sylvain.ploux@chu-bordeaux.fr name: Estel HUGOT role: CONTACT phone: (0)5 57 62 32 26 phoneExt: +33 email: estel.hugot@chu-bordeaux.fr name: Sylvain MD Ploux role: PRINCIPAL_INVESTIGATOR lat: 44.81011 lon: -0.64129 hasResults: False
nctId: NCT06272331 id: NL83162.091.22 briefTitle: Milk and Plant Protein Digestion acronym: MAPP-D overallStatus: RECRUITING date: 2024-01-15 date: 2024-07-01 date: 2024-07-01 date: 2024-02-22 date: 2024-02-22 name: Wageningen University class: OTHER name: FrieslandCampina briefSummary: The goal of this study is to explore the effect of protein quantity and quality in plant-based drinks. Healthy normal-weight males aged between 18 and 45 years will be included in the study.
Participants will visit after an overnight fast three times and have blood draws before and after consumption one of the study drinks. There will be MRI scans of the stomach before and after consumption of the drink to assess gastric behavior. conditions: Food Digestion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 12 type: ESTIMATED name: Low-protein plant-based drink name: High-protein plant-based drink name: Cow's milk measure: Postprandial plasma amino acid profile as characterized by the peak height and iAUC measure: Gastric behavior measure: Postprandial plasma response measure: Verbal ratings of wellbeing measure: MRI markers of digestion sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Human Research Unit - Division of Human Nutrition and Health status: RECRUITING city: Wageningen zip: 6708WE country: Netherlands name: Paul Smeets, PhD role: CONTACT phone: + 31317484681 email: paul.smeets@wur.nl name: Paul Smeets, PhD role: PRINCIPAL_INVESTIGATOR lat: 51.97 lon: 5.66667 hasResults: False
nctId: NCT06272318 id: 74131 briefTitle: Vital Signs Blood Pressure Trial overallStatus: NOT_YET_RECRUITING date: 2024-02-20 date: 2024-06-30 date: 2026-12-31 date: 2024-02-22 date: 2024-02-22 name: Stanford University class: OTHER briefSummary: The purpose of this study is collect subject vitals with a blood pressure cuff, electrocardiogram (ECG), and photoplethysmogram (PPG). This data can then be used to develop a reliable, accurate, noninvasive, and continuous blood pressure monitoring device. conditions: Cardiovascular Diseases conditions: Hypertension conditions: Blood Pressure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Blood Pressure Cuff, EKG, PPG measure: Collection of Subject Name (optional) measure: Collection of Subject Height measure: Collection of Subject Weight measure: Collection of Subject Age measure: Collection of Subject Medical Comorbidities measure: Blood Pressure Measurement measure: Collection of ECG Waveforms measure: Collection of PPG Waveforms sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT hasResults: False
nctId: NCT06272305 id: 49RC21_0301 briefTitle: TREC - Evaluation of the Impact of Eversion Technical Features on the Rate of Carotid Restenosis acronym: TREC overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-06-01 date: 2024-06-01 date: 2024-02-22 date: 2024-02-22 name: University Hospital, Angers class: OTHER_GOV briefSummary: Restenosis due to myo-intimal hyperplasia remains a concern after carotid endarterectomy. It occurs in around 6% of cases. Several risk factors for restenosis have already been identified, such as smoking, hypertension, female gender, diabetes, dyslipidemia and small carotid diameter. The main objective of this prospective multicenter study was to determine whether the technical characteristics of the eversion technique have an influence on the rate of restenosis at 1 year.
Between September 2021 and November 2022, we followed all patients undergoing carotid endarterectomy by eversion in 8 French hospitals. Demographic data, operative indications and technical characteristics of the endarterectomies performed were collected. These were defined by the circumferential nature of the carotid bulb according to 3 types (TREC A, B or C), and the length and depth of the endarterectomy according to anatomopathological reports. Post-operative complications were collected as much as doppler ultrasonography at three months and 1 year to quantify restenosis. conditions: Hyperplasia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 500 type: ESTIMATED name: This research does not require any specific investigation and does not imply any modification of treatment. measure: Rate of restenosis measure: Morbidity and mortality rate measure: Major cardiological event measure: Minor neurological events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06272292 id: S66441 briefTitle: Biomechanical Investigation of Symptomatic FAI and Two Groups of Asymptomatic Controls acronym: CAM-FAI adult overallStatus: RECRUITING date: 2022-07-28 date: 2024-03-01 date: 2024-03-01 date: 2024-02-22 date: 2024-02-22 name: Universitaire Ziekenhuizen KU Leuven class: OTHER briefSummary: Femoroacetabular impingement (FAI) is an orthopaedic condition that is primarily characterized by the presence of anatomic bony abnormalities in the femoral head and/or the acetabulum resulting in an abnormal contact between the two during hip motion, especially in positions of increased hip flexion and rotation, ultimately leading to hip pain. Unfortunately, a FAI diagnosis is frequently only made once symptoms have become severe to an extent that they limit everyday life activities. Moreover, another important aspect that has been consistently overlooked in past FAI movement studies is the influence muscle strength and activation can have on movement pattern and symptom presentation. The diagnosis and management of FAI needs to be addressed through a more wholesome investigation of the biomechanical influence on the manifestation of symptoms.
This project aims to further unravel the link between spinopelvic anatomy, its biomechanical contribution to femoro-pelvic motion and the manifestation of femoroacetabular impingement in adult male population. By, for the first time, integrating three-dimensional (3D) instrumented motion analysis with state-of-the-art full-body biplanar X-ray imaging (EOS imaging, Paris France), we will more specifically investigate the presence of an association between spinopelvic kinematics and the link to symptomatic FAI morphology, as well as investigate the presence of differences in these measures between symptomatic and asymptomatic subjects with comparable femoral morphology. conditions: Femoroacetabular Impingement studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Cross-sectional, case-control prospective clinical study primaryPurpose: DIAGNOSTIC masking: SINGLE maskingDescription: 3 study groups, based on clinical examination and medical imaging:
* healthy controls whoMasked: PARTICIPANT count: 99 type: ESTIMATED name: EOS name: 3D motion lab analysis measure: The presence of CAM morphology in combination with symptoms measure: The Copenhagen Hip and Groin Outcome Score (HAGOS) measure: Radiographic spinopelvic parameters measure: 3D motion analysis parameters sex: MALE minimumAge: 21 Years maximumAge: 35 Years stdAges: ADULT facility: University Hospitals of Leuven status: RECRUITING city: Leuven state: Vlaams-Brabant zip: 3000 country: Belgium name: Stijn Ghijselings, MD role: CONTACT phone: +32 16 33 88 18 email: stijn.ghijselings@uzleuven.be name: Orthopedic Research role: CONTACT phone: +32 16 33 88 18 email: orthopedie.research@uzleuven.be lat: 50.87959 lon: 4.70093 hasResults: False
nctId: NCT06272279 id: HS23666(B2020:015) briefTitle: Neuromodulation With Spinal Stimulation Methods overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2025-02-01 date: 2024-02-22 date: 2024-02-22 name: University of Manitoba class: OTHER briefSummary: This is a pilot research study to test the protocols needed for transcutaneous spinal electrical stimulation in persons living with spinal cord injury (SCI). Up to 24 participants will be enrolled. A variety of stimulation parameters and outcome measures will be assessed. conditions: Spinal Cord Injuries conditions: Spinal Cord Injury at C5-C7 Level conditions: Paraplegia, Spinal conditions: Paraplegia, Incomplete studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Semi-blinded, randomized block entry design, crossover intervention study. primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: The participant will be connected to the stimulation device(s) but will not know if it has been turned on during each trial. In addition, the person analyzing the outcome data will not be aware of the stimulation status of the participant. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: spinal stimulation-DCS name: spinal stimulation-sham DCS name: spinal stimulation-EPS name: sham spinal stimulation-EPS measure: Motor response measure: Motor evoked potentials measure: Blood pressure sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Manitoba status: ENROLLING_BY_INVITATION city: Winnipeg state: Manitoba zip: R3E 0J9 country: Canada lat: 49.8844 lon: -97.14704 facility: University of Manitoba status: RECRUITING city: Winnipeg state: Manitoba zip: R3E 0J9 country: Canada name: Katinka Stecina, Ph.D. role: CONTACT phone: 2047893761 email: Katinka.Stecina@umanitoba.ca name: Kristine Cowley, Ph.D. role: CONTACT phone: 2047893305 email: Kristine.Cowley@umanitoba.ca lat: 49.8844 lon: -97.14704 hasResults: False
nctId: NCT06272266 id: 2021/03-26 briefTitle: The Aerobic Exercise Capacity and Muscle Strenght in Individuals With COVID-19 overallStatus: COMPLETED date: 2022-04-20 date: 2022-05-30 date: 2023-02-15 date: 2024-02-22 date: 2024-02-22 name: Selda Sarıkaya class: OTHER name: Zonguldak Bulent Ecevit University briefSummary: The subject of the project is the impact of COVID-19 on the exercise capacity of patients. The long-term sequelae of COVID-19 infection are still unknown. It is not yet clear whether pulmonary sequelae, which may be a consequence of the disease, are associated with a measurable functional deficit. In this project, the aerobic capacity of healthy people will be compared with individuals who have experienced Covid-19, and the amount of increase in aerobic capacity will be determined at the end of 15 sessions by applying a rehabilitation program including bicycle ergometry to individuals who have experienced Covid-19 Detailed description : In December 2020, in the pneumonia epidemic in which the city of Wuhan, China is the center, pneumonia developed due to the newly defined SARS-CoV-2 factor was defined as Coronavirus disease 2019 (COVID-19). It has been observed that clinical findings of SARS-CoV-2 infection in patients hospitalized in Wuhan range from mild manifestations such as asymptomatic disease and mild upper respiratory tract infection to severe viral pneumonia accompanied by respiratory failure and may result in death.The long-term sequelae of COVID19 are still unknown. Pulmonary sequelae that impair physical fitness have been predominantly defined for hospitalized patients with COVID-19. Although lung lesions have been identified as asymptomatically in infected individuals, it is not yet clear whether these observations are related to a measurable functional deficit in physical fitness. They measured the change in the predicted maximum aerobic capacity (VO2 max) of non-infected,asymptomatically infected, and recovering COVID-19 individuals with a well-established and validated physical fitness test before and after the COVID-19 outbreak among young Swiss adults.They demonstrated decreased aerobic capacity in young adults 1 to 2 months after symptomatic COVID-19 without physical strength being affected. In their study, 19% of young adults who recovered after COVID-19 had a VO2 max decrease of more than 10% compared to baseline before infection. It has been identified that decreased VO2 max value is the hallmark of interstitial lung disease. SARS-CoV-2 infection causes lung damage even in asymptomatic cases.
A total of 64 people, including 32 people in 2 groups between the ages of 18-55, who have or have not had corona virus infection, who applied to Bülent Ecevit University Faculty of Medicine Physical Therapy and Rehabilitation or Infectious Diseases outpatient clinics for different reasons, will be included in our project. The research start date is February 2021 and the end date is February 2023. At the beginning of the study, demographic information of the individuals such as gender, age,height, weight, occupation, education, body mass index, physical activity level (international physical activity index-IPAQ), the most used hand (dominant hand) in daily life activities will be recorded. In the control group, resting heart rate, blood pressure, saturation measurement, ECG will be performed before exercise. In addition, in order to evaluate their muscle strength, microFET3 manual muscle measurement device will be used to measure the triceps muscle strength in the upper extremity they actively use, and the quadriceps muscle strength of the same side will be measured, and their grip strength will be measured with the JAMAR hydraulic hand dynamometer. Using the international physical activity index(IPAQ), activity status in daily life will be assessed. The exercise capacity of all individuals will be measured with the aid of the COSMED Quark CPET device using the bicycle ergometry test recommended by the American Society of Cardiovascular and Pulmonary Rehabilitation. In this test, submaximal exercise test will be performed by providing 25 W increase in 2 minutes periods after the warm-up period at 0 load (W) for 2 minutes. In addition, the borg scale obtained at the end of the test, metabolic equivalent of task (MET) and maximum work (W), test duration, maximum heart rate parameters will also be recorded in order to evaluate the exercise capacity.
nctId: NCT06272253 id: UNAIR-MP-INAKTIF-R-010 briefTitle: UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects overallStatus: ACTIVE_NOT_RECRUITING date: 2023-09-19 date: 2024-03-19 date: 2024-07-19 date: 2024-02-22 date: 2024-02-22 name: Dr. Soetomo General Hospital class: OTHER_GOV name: Indonesia-MoH name: Universitas Airlangga name: PT Biotis Pharmaceuticals, Indonesia briefSummary: This is an open label trial. There will only be 1 group in the study. All subjects will receive INAVAC vaccine and be followed for 6 months.
The vaccine will be administered intramuscularly. This study will be started after the interim analysis of the phase III INAVAC trial in adolescent. This study will have two interim and one full analysis reports. conditions: COVID-19 Pandemic conditions: COVID-19 Vaccines studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 250 type: ACTUAL name: INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg measure: Humoral Immune Response (Neutralizing antibody) measure: Incidence of Adverse Events measure: Humoral Immune Response - The neutralizing antibody measure: Humoral Immune Response-IgG SARS-CoV-2 neutralizing titer by CLIA measure: Exploratory Endpoints-Whole Genome Sequencing sex: ALL minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD facility: Dr. Soetomo General Hospital city: Surabaya state: Jawa Timur zip: 67161 country: Indonesia lat: -7.24917 lon: 112.75083 hasResults: False
nctId: NCT06272240 id: 17380 briefTitle: Tumor Microenvironment in Ovarian Cancer acronym: MICO overallStatus: RECRUITING date: 2024-01-02 date: 2024-07 date: 2027-01 date: 2024-02-22 date: 2024-02-22 name: University of Udine class: OTHER briefSummary: A detailed understanding of molecular mechanism of cancer genesis is fundamental to develop innovative and personalized therapies. The new frontier in biomedical research is represented by organoids, a three-dimensional cell culture system obtained from a tissue fragment that accurately reproduces the essential properties of the original tissue in vitro, which could provide a valuable model for explanation of ovarian cancers pathogenesis and will allow to predict the response to a specific therapy. With this research project, we expect to generate ovarian cancer organoids to characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules). conditions: Ovarian Cancer Stage III conditions: Ovarian Cancer Stage IV studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Ovarian Cancer Organoids measure: • Composition of the tumor microenvironment (including the immune system and intratumoral microbiota). • Generate organoids sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Università degli Studi di Udine status: RECRUITING city: Udine state: UD zip: 33100 country: Italy lat: 46.0693 lon: 13.23715 hasResults: False
nctId: NCT06272227 id: 4-2023-0986 briefTitle: Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients overallStatus: NOT_YET_RECRUITING date: 2024-02-13 date: 2025-09-01 date: 2025-09-01 date: 2024-02-22 date: 2024-02-22 name: Yonsei University class: OTHER briefSummary: This study aims to investigate the potential improvement in muscle function, compared to the placebo group, through the concurrent administration of denosumab and alfacalcidol over a one-year period in postmenopausal women with functional sarcopenia and osteoporosis aged 65 and older. The study is planned as a double-blinded randomized controlled trial, intending to recruit a total of 340 participants. Primary outcome is the improvement in SPPB score of 0.5 or more compared to the control group. conditions: Sarcopenia studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 340 type: ESTIMATED name: alfacalcidol name: placebo name: Denosumab measure: Improvement in SPPB score of 0.5 or more compared to the control group sex: FEMALE minimumAge: 65 Years stdAges: OLDER_ADULT facility: Division of Endocrinology, Department of internal Medicine, Yonsei University College of Medicine, Severance Hospital city: Seoul zip: 03722 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06272214 id: ZJCCRT005 briefTitle: Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2027-03-01 date: 2029-03-01 date: 2024-02-22 date: 2024-02-22 name: Zhejiang Cancer Hospital class: OTHER briefSummary: This study is a multicenter, prospective, randomized phase II trial aimed at exploring the value of adjuvant radiotherapy in patients at high risk of recurrence after neoadjuvant chemoradiotherapy for esophageal cancer. The study primarily includes patients with esophageal cancer who underwent neoadjuvant chemoradiotherapy and surgery and did not achieve complete pathological response (non-pCR) postoperatively and were defined as preoperative clinical stage at T3-4N+M0.